FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2500173826> ?p ?o ?g. }

• W2500173826 abstract "CTLA-4 is an important negative regulator of T cell function. Together with CD28, these two co-receptors exemplify a co-inhibitory/stimulatory system that is critical in the regulation of T cell immune responses. Key to this regulatory system are the shared ligands, CD80 and CD86, whose engagement determines whether T cells receive stimulatory (CD28) or inhibitory (CTLA-4) signals. Pre-clinical and clinical studies have shown that anti-CTLA-4 antibodies can enhance tumor-specific immunity through a combination of mechanisms including: 1) blockade and or displacement of CD80/CD86 binding to CTLA-4, leading to CD28 activation; 2) prevention of the trans-endocytosis of CD80/CD86 from the surface of antigen presenting cells by CTLA-4 expressing regulatory T cells; and 3) the selective depletion of CTLA-4 expressing intratumoral regulatory T cells by an Fcγ receptor-mediated mechanism. AGEN1884 and AGEN2041, two fully human anti-CTLA-4 antibodies identified using the Retrocyte Display™ platform, are being developed for the treatment of advanced malignancies. The antibodies share heavy and light chain complementarity determining regions (CDRs), but differ in their IgG Fc region (AGEN1884, an IgG1, and AGEN2041, an IgG2). AGEN1884 and AGEN2041 selectively bind to human and cynomolgus monkey CTLA-4 with low single digit nM affinity. Further, both antibodies bind CTLA-4 expressed on T cells, and potently block engagement of CD80 and CD86, leading to enhanced T cell responsiveness. In a T cell-dependent antibody response (TDAR) study in cynomolgus monkeys, administration of a vaccine in combination with either AGEN1884 or AGEN2041 augmented the antibody response to the vaccine antigen. This finding demonstrates that both antibodies are functional in non-human primates, and exemplifies their utility in promoting immunity to co-administered antigens in patients, such as therapeutic cancer vaccines. Consistent with this, an anti-mouse CTLA-4 antibody produced potent tumor regressions in combination with a heat-shock protein-based vaccine (a surrogate vaccine resembling Prophage™ heat shock protein-based autologous vaccine). The distinct IgG backbones of AGEN1884 and AGEN2041 enable distinct optimal effector functions, such as the ability to mediate antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). We anticipate that these differences in effector function may be exploited in certain tumors depending on immune cell composition. Taken together, the biochemical and functional attributes of AGEN1884 and AGEN2041 are ideally suited for clinical development, both as single agents and also in combination with other immune education approaches, such as cancer vaccines and immunomodulatory antibodies or small molecule therapies. Citation Format: Elise E. Drouin, Ana Gonzalez, Hao Tang, David Savitsky, Randi Gombos, Jeremy Waight, Benjamin Duckless, Andrea Schuster, Lili Wang, Shiwen Lin, Cornelia Mundt, Gerd Ritter, Taha Merghoub, Kyle Draleau, Jedd Wolchok, Daniel Levey, Jennifer Buell, Marc van Dijk, John M. Goldberg, Robert Stein, Nicholas S. Wilson. AGEN1884 and AGEN2041: Two functionally distinct anti-CTLA-4 antagonist antibodies. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 5005." @default.
• W2500173826 created "2016-08-23" @default.
• W2500173826 creator A5002916213 @default.
• W2500173826 creator A5002951130 @default.
• W2500173826 creator A5015188825 @default.
• W2500173826 creator A5019781455 @default.
• W2500173826 creator A5023492006 @default.
• W2500173826 creator A5024278799 @default.
• W2500173826 creator A5025097010 @default.
• W2500173826 creator A5032317765 @default.
• W2500173826 creator A5034856153 @default.
• W2500173826 creator A5044464936 @default.
• W2500173826 creator A5045291162 @default.
• W2500173826 creator A5046912050 @default.
• W2500173826 creator A5054656505 @default.
• W2500173826 creator A5059122102 @default.
• W2500173826 creator A5060590115 @default.
• W2500173826 creator A5068969141 @default.
• W2500173826 creator A5074364628 @default.
• W2500173826 creator A5077755946 @default.
• W2500173826 creator A5088931436 @default.
• W2500173826 creator A5089613838 @default.
• W2500173826 creator A5090057851 @default.
• W2500173826 date "2016-07-15" @default.
• W2500173826 modified "2023-09-26" @default.
• W2500173826 title "Abstract 5005: AGEN1884 and AGEN2041: Two functionally distinct anti-CTLA-4 antagonist antibodies" @default.
• W2500173826 doi "https://doi.org/10.1158/1538-7445.am2016-5005" @default.
• W2500173826 hasPublicationYear "2016" @default.
• W2500173826 type Work @default.
• W2500173826 sameAs 2500173826 @default.
• W2500173826 citedByCount "0" @default.
• W2500173826 crossrefType "proceedings-article" @default.
• W2500173826 hasAuthorship W2500173826A5002916213 @default.
• W2500173826 hasAuthorship W2500173826A5002951130 @default.
• W2500173826 hasAuthorship W2500173826A5015188825 @default.
• W2500173826 hasAuthorship W2500173826A5019781455 @default.
• W2500173826 hasAuthorship W2500173826A5023492006 @default.
• W2500173826 hasAuthorship W2500173826A5024278799 @default.
• W2500173826 hasAuthorship W2500173826A5025097010 @default.
• W2500173826 hasAuthorship W2500173826A5032317765 @default.
• W2500173826 hasAuthorship W2500173826A5034856153 @default.
• W2500173826 hasAuthorship W2500173826A5044464936 @default.
• W2500173826 hasAuthorship W2500173826A5045291162 @default.
• W2500173826 hasAuthorship W2500173826A5046912050 @default.
• W2500173826 hasAuthorship W2500173826A5054656505 @default.
• W2500173826 hasAuthorship W2500173826A5059122102 @default.
• W2500173826 hasAuthorship W2500173826A5060590115 @default.
• W2500173826 hasAuthorship W2500173826A5068969141 @default.
• W2500173826 hasAuthorship W2500173826A5074364628 @default.
• W2500173826 hasAuthorship W2500173826A5077755946 @default.
• W2500173826 hasAuthorship W2500173826A5088931436 @default.
• W2500173826 hasAuthorship W2500173826A5089613838 @default.
• W2500173826 hasAuthorship W2500173826A5090057851 @default.
• W2500173826 hasConcept C147483822 @default.
• W2500173826 hasConcept C148125776 @default.
• W2500173826 hasConcept C154317977 @default.
• W2500173826 hasConcept C159654299 @default.
• W2500173826 hasConcept C202751555 @default.
• W2500173826 hasConcept C203014093 @default.
• W2500173826 hasConcept C21705690 @default.
• W2500173826 hasConcept C2776090121 @default.
• W2500173826 hasConcept C2778297628 @default.
• W2500173826 hasConcept C2780405999 @default.
• W2500173826 hasConcept C2781101188 @default.
• W2500173826 hasConcept C39347974 @default.
• W2500173826 hasConcept C502942594 @default.
• W2500173826 hasConcept C55493867 @default.
• W2500173826 hasConcept C86803240 @default.
• W2500173826 hasConcept C8891405 @default.
• W2500173826 hasConcept C95444343 @default.
• W2500173826 hasConceptScore W2500173826C147483822 @default.
• W2500173826 hasConceptScore W2500173826C148125776 @default.
• W2500173826 hasConceptScore W2500173826C154317977 @default.
• W2500173826 hasConceptScore W2500173826C159654299 @default.
• W2500173826 hasConceptScore W2500173826C202751555 @default.
• W2500173826 hasConceptScore W2500173826C203014093 @default.
• W2500173826 hasConceptScore W2500173826C21705690 @default.
• W2500173826 hasConceptScore W2500173826C2776090121 @default.
• W2500173826 hasConceptScore W2500173826C2778297628 @default.
• W2500173826 hasConceptScore W2500173826C2780405999 @default.
• W2500173826 hasConceptScore W2500173826C2781101188 @default.
• W2500173826 hasConceptScore W2500173826C39347974 @default.
• W2500173826 hasConceptScore W2500173826C502942594 @default.
• W2500173826 hasConceptScore W2500173826C55493867 @default.
• W2500173826 hasConceptScore W2500173826C86803240 @default.
• W2500173826 hasConceptScore W2500173826C8891405 @default.
• W2500173826 hasConceptScore W2500173826C95444343 @default.
• W2500173826 hasLocation W25001738261 @default.
• W2500173826 hasOpenAccess W2500173826 @default.
• W2500173826 hasPrimaryLocation W25001738261 @default.
• W2500173826 hasRelatedWork W2129620510 @default.
• W2500173826 hasRelatedWork W2147959368 @default.
• W2500173826 hasRelatedWork W2489250614 @default.
• W2500173826 hasRelatedWork W2501578153 @default.
• W2500173826 hasRelatedWork W2546494539 @default.
• W2500173826 hasRelatedWork W2547551854 @default.
• W2500173826 hasRelatedWork W2739498537 @default.
• W2500173826 hasRelatedWork W2740554793 @default.
• W2500173826 hasRelatedWork W2795781326 @default.
• W2500173826 hasRelatedWork W2809733766 @default.

• next